The agreement includes close collaboration with Roche scientists to advance the capabilities of GastroPlus in the area of simulating drug-drug interactions.
Walt Woltosz, chairman and CEO of Simulations Plus, said: “This collaboration will provide funding and data to enable us to move GastroPlus to the forefront in the prediction of drug-drug interactions. Simulations Plus will also contribute to this effort from our in-house R&D funds. Drug-drug interactions are one of the most critical aspects of bringing new drugs to market.”